Lv3
296 积分 2021-03-05 加入
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
10小时前
已完结
Assessing adverse event burden in chronic lymphocytic leukemia treatment regimens: what’s best for patient quality of life?
13天前
已完结
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
1个月前
已完结
Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges
1个月前
已完结
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
1个月前
已完结
Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment
1个月前
已完结
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
1个月前
已完结
Emerging role of EZH2 in solid tumor metastasis
4个月前
已完结
Establishment and Culture of Leukemia–Lymphoma Cell Lines
5个月前
已完结
Regulatory Toxicology and Pharmacology New limits proposed for the management of non-mutagenic impurities
5个月前
已完结
皖公网安备34019202002308
